Next-generation mRNA Design – Increasing mRNA Potency with a New Cap Analog

Kate Broderick, PhD, Chief Innovation Officer, Maravai LifeSciences

Next-generation mRNA Design – Increasing mRNA Potency with a New Cap Analog

Click video to watch

Kate Broderick, PhD, Chief Innovation Officer, Maravai LifeSciences
Dr. Kate Broderick has more than 15 years of experience in the life science industry. A recognized vaccine expert, Dr. Broderick has a broad background in device and product development in the DNA therapeutic and drug delivery field. Prior to joining Maravai in 2022, Dr. Broderick held roles of increasing responsibility at Inovio Pharmaceuticals, most recently as Senior Vice President, R&D. Dr. Broderick has served as a principal investigator for a variety of grants and awards from government agencies and non-profits, including the National Institutes of Health. She received her PhD from the University of Glasgow in Scotland and completed her post-doctoral research at the University of California, San Diego.

mRNA vaccines and therapeutics are expanding rapidly, in part fueled by the success of COVID-19 vaccines. An essential part of any mRNA therapeutic is the 5’ cap structure, which is critical to the stability and expression of an mRNA. Learn more about how major capping strategies differ in their manufacturing costs, time, complexity, and availability, and how TriLink BioTechnologies is continuing to innovate in this technology as we debut a novel Cap1 structure.